Type: Breast cancer
Shirley Baxter talks about representing consumers in deciding what research Cancer Council funds.
A team of researchers led by Dr Nicole Verrills has been investigating if a new ‘gene marker’ can predict which breast cancer patients may have poorer treatment outcomes.
Research has revealed the cost of cancer to the Australian health system to be over $6 billion a year.
This project will provide the critical clinical evidence on the effectiveness of adding progesterone to antiestrogenic therapies in patients with early stage breast cancer.
This research builds on previous findings that the protein MCL-1 acts like a life and death switch for triple negative breast cancer cells.
This study will explore whether certain microRNAS could be targeted in combination with chemotherapy to kill breast cancer cells and improve patient outcomes.
Professor Bettina Meiser is leading a world-first study on the impacts of testing women for common, low-risk genetic variants that can lead to breast cancer.
Professor Christopher Ormandy is driving the next generation of revolutionary breast cancer treatments. His team has identified pathways that turn normal breast cells into cancer.
Chemotherapy is the most common treatment for triple negative breast cancer, but the disease often comes back. Prof Baxter’s team is studying possible new drug combinations.